X

ICYMI: Multi-stakeholder group recommended changes to support value-driven health care

Michelle Drozd   |     September 14, 2016   |   SHARE THIS

PhRMA_Value_Collaborative_Reversed.jpg
As part of PhRMA’s efforts to explore policy solutions to promote value-driven health care, we recently participated in a forum convened by Deloitte and the Network for Excellence in Health Innovation, which also included leaders from plans, health providers, academia, patient groups, non-profits and the medical device industry, to discuss how a value-driven health care system can be built in a way that supports innovation. 

Several recommendations were discussed, which would allow evolution of the competitive, private health care market to become increasingly driven by value. 

  1. Incorporate more clinical quality measures tied to long-term clinical outcomes in new payment models.
  2. Expedite development of patient-centered measures reflecting a broad array of patient preferences.

  3. Clarify the requirements for generating and communicating economic evidence.

  4. Consider life sciences companies as partners in care delivery and identifying unmet or under-met needs.

  5. Accelerate the adoption of value-based purchasing agreements with private health plans or providers.

Read the full white paper summarizing these recommendations here.

Michelle Drozd

Michelle Drozd Michelle Drozd is a Deputy Vice President in the Policy and Research department at the PhRMA where she focuses on the evolving healthcare system and how to improve the use of medicines. Prior to joining PhRMA, she worked at Partners Healthcare and RTI International in Boston. Michelle spends her free time reading and doing house projects with her husband and two boys.

Topics: Value-Driven Health Care, Policy Solutions, The Value Collaborative

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates